Related Experiment Video

Updated: Aug 29, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments

Chia-Hsin Liu1, Shu-Hsuan Liu1, Yo-Liang Lai2,3

  • 1Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.

Computational and Structural Biotechnology Journal
|September 12, 2022
PubMed

Insights

Researchers identified a four-microRNA (miRNA) panel to predict lung adenocarcinoma survival. This panel effectively inhibits cancer cell growth and metastasis, showing significant therapeutic potential for lung cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer, particularly lung adenocarcinoma (LUAD), is a leading cause of cancer mortality globally.
  • MicroRNAs (miRNAs) are crucial regulators of gene expression and are implicated in various cancers, presenting potential therapeutic targets.
  • Identifying specific miRNAs linked to poor prognosis is essential for developing targeted LUAD therapies.

Purpose of the Study:

  • To identify and validate a panel of microRNAs (oncomiRs) associated with poor 5-year overall survival in lung adenocarcinoma (LUAD).
  • To evaluate the therapeutic potential of a novel four-miRNA panel in preclinical models of LUAD.

Main Methods:

  • Differential expression analysis of miRNAs in LUAD patient samples to identify candidates linked to survival outcomes.
  • Statistical evaluation of miRNA combinations for predicting 5-year overall survival.
  • In vitro studies using cell lines and in vivo experiments in animal models to assess the therapeutic effects of antagomiRs targeting the identified miRNAs.

Main Results:

  • A four-miRNA panel (miR-9-5p, miR-1246, miR-31-3p, and miR-3136-5p) was identified, significantly outperforming single miRNAs in predicting 5-year overall survival in LUAD patients (HR: 3.47, p=0.000271).
  • Transfection with antagomiRs targeting these miRNAs individually inhibited LUAD cell growth, migration, and invasion.
  • Combined antagomiR treatment demonstrated a synergistic effect, significantly reducing cell proliferation and tumor growth, and decreasing metastatic ability in vivo.

Conclusions:

  • The identified four-miRNA panel serves as a promising biomarker for predicting LUAD patient survival.
  • Targeting these specific oncomiRs with antagomiRs exhibits significant therapeutic potential for inhibiting LUAD progression and metastasis.
  • These findings support the development of oncomiR-based diagnostics and therapeutics for lung adenocarcinoma.
Keywords:
Lung adenocarcinomaantagomiRmiRNA treatmentoncomiR

More Related Videos

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.8K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.4K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.8K